The challenge of subgroup analyses--reporting without distorting
about
Prone position for acute respiratory failure in adultsCalcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysisAntiplatelet therapy in acute coronary syndromes: focus on ticagrelorFrom Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in OncologyEvolving perspectives on clopidogrel in the treatment of ischemic strokeSex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analysesEffect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine TrialEffect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial.Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunctionPre-referral rectal artesunate in severe malaria: flawed trial.Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.Aggregate-data estimation of an individual patient data linear random effects meta-analysis with a patient covariate-treatment interaction term.Using clinical trial data to tailor adjuvant treatments for individual patients.Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols.Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer.Carotid endarterectomy benefits patients with CKD and symptomatic high-grade stenosis.Regularized outcome weighted subgroup identification for differential treatment effects.Assessing Heterogeneity of Treatment Effects: Are Authors Misinterpreting Their Results?A basic study design for expedited safety signal evaluation based on electronic healthcare data.Bayesian variable selection in cost-effectiveness analysis.Perinatal systemic inflammatory response syndrome and retinopathy of prematurity.Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trialPredicting response to a cognitive-behavioral approach to treating low back pain: Secondary analysis of the BeST data set.Subgroup identification from randomized clinical trial data.Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set.Calcium supplements and cardiovascular risk: 5 years onDetecting moderator effects using subgroup analyses.Chains of evidence, mosaics of data: does estrogen 'cause' breast cancer? How would we know?Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment optionsEvaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.Associations between the CYP17, CYPIB1, COMT and SHBG polymorphisms and serum sex hormones in post-menopausal breast cancer survivors.Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials.Subgroup analysis of large trials can guide further research: a case study of vitamin E and pneumoniaA randomized trial of parental behavioral counseling and cotinine feedback for lowering environmental tobacco smoke exposure in children with asthma: results of the LET'S Manage Asthma trial.Associations of insulin resistance and adiponectin with mortality in women with breast cancer.Decreased response to inhaled steroids in overweight and obese asthmatic childrenInpatient hospitalization in addiction treatment for patients with a history of suicide attempt: a case of support for treatment performance measures.Mixing nulliparous and multiparous women in randomised controlled trials of preeclampsia prevention is debatable: evidence from a systematic review.Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trialImproving Patient Care Using the Johnson-Neyman Analysis of Heterogeneity of Treatment Effects According to Individuals' Baseline Characteristics
P2860
Q24187780-1F220461-D48A-4F07-B68A-261EC83BA1F8Q24548778-51448CD7-8A4F-46ED-AAC1-F8BE73B9AFE9Q24605508-0CF3D955-D9BC-419D-946A-2D455201D553Q26797522-F4C15BC7-A176-485D-95F9-2929D5E86B9AQ28217627-13722E9D-38A4-4935-A54E-A59517FEAC50Q28593306-20C46A25-EE8B-46A7-8C77-F72999F5CAD6Q28607942-B2B5F2ED-DA48-481A-987A-F481A7170EFCQ30352609-71C6DD9D-933B-4742-A023-3365A9338BE5Q30471494-EFDED4AA-232A-4094-B34E-0D436076A999Q30504139-E849B657-F9BA-4EA8-BFAD-4DBE73B26906Q30514241-ADEBE679-561E-4C13-81E8-284094501BADQ30570037-B52F0B1E-8097-44F3-BA3E-C38D9CE9BD44Q31122593-F95DE05E-1AE7-42B8-A833-2CC8A1395EFBQ33389750-309CCB3D-4E17-4A32-BCB5-D022BAB8F846Q33490603-3334080E-BC44-437F-9842-502930606FF1Q33562172-E39823FE-EAF0-4794-8C3B-53023EDB07EDQ33575291-057D7120-9F70-4988-82C3-A12A06DB00F4Q33618795-620DEBB9-5820-4D5D-BD3E-39BCE93FAF5DQ33648230-14A1537C-3F3E-4329-AF96-981C9A2B584AQ33859002-0B5BE94A-432A-4817-96C1-1FAB276A8034Q33865624-D7B782DE-8C82-42BF-8BD5-1BD97709E5ECQ33914033-FCD2219B-4F8E-4928-B1AB-0803AF53D070Q33931900-50DB1122-1204-4AC2-BC6E-C7139C29DC8DQ33981752-6E9D2A81-4DF1-477D-8036-BD02076B3183Q34006795-FEB7EC25-D6B1-4F69-9585-2B1E6C78777CQ34016231-2B18D5C1-B179-42EA-A180-3E18FE72BB8AQ34184426-A2E99924-7092-4391-B479-0B8FD389B2B3Q34285969-11F45E96-1F90-4DFF-9CB7-12A7BE4DA0B8Q34286130-4345B8D5-1587-467E-8AC9-9F5AB3554630Q34334964-089749B5-66E5-442A-A873-2609404DF1BCQ34383204-ED519853-583D-4B3D-8309-B24E9798717BQ34588697-35AB246B-4EBC-49A2-B9C8-BE8D0A25A0D6Q34612178-58A157B2-7528-4E3B-B50C-C039BAF23600Q34617430-4F8CBEB2-B0DA-4030-A6FB-75DE42C2C281Q34662835-C774BDBC-4D1B-42F0-B7D5-71001C2CEA6AQ34665187-D1FB940A-0729-4D73-B8F6-21F0334B4232Q34763281-3E022D1D-68A9-4000-B936-34E63B86152EQ34795816-B246439E-8F32-42B6-A799-0954D76BFC51Q34991783-8641DE47-25AE-4A15-963F-9237CF500DD5Q35105710-7B7F1E82-8DAD-48B5-9C52-6EE8FFE477EA
P2860
The challenge of subgroup analyses--reporting without distorting
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The challenge of subgroup analyses--reporting without distorting
@ast
The challenge of subgroup analyses--reporting without distorting
@en
The challenge of subgroup analyses--reporting without distorting
@nl
type
label
The challenge of subgroup analyses--reporting without distorting
@ast
The challenge of subgroup analyses--reporting without distorting
@en
The challenge of subgroup analyses--reporting without distorting
@nl
prefLabel
The challenge of subgroup analyses--reporting without distorting
@ast
The challenge of subgroup analyses--reporting without distorting
@en
The challenge of subgroup analyses--reporting without distorting
@nl
P356
P1476
The challenge of subgroup analyses--reporting without distorting
@en
P2093
Stephen W Lagakos
P304
P356
10.1056/NEJMP068070
P407
P577
2006-04-20T00:00:00Z